Navigation Links
QIAGEN Offers Clinical Labs Early Access to New Ingenuity Solution for Streamlined Interpretation of Patient Sequencing Data
Date:11/13/2013

labs is to efficiently sift through huge amounts of data and extract high-confidence, actionable answers," said Sean Scott, Senior Vice President of Business Development at QIAGEN Redwood City. "This new solution will simplify and streamline the interpretation and reporting process and provide consistent, high-quality and actionable results for use in clinical research and decision making."

The new interpretation and reporting solution draws upon the vast clinical and genomic data in the expert-curated Ingenuity Knowledge Base. It will be the first product in the Ingenuity portfolio that is specifically designed to address major challenges of scale, speed and decision support that healthcare laboratories face with the adoption of NGS-based applications. The time required to make accurate clinical assessments of variants - especially as tests move from single-gene to multiple-gene to panels, exomes and whole genomes - is becoming a fundamental bottleneck and is slowing the adoption of these data in clinical applications. The new solution will provide clinical labs with automated scoring, interpretation and reporting of findings in standardized, HIPAA Safe Harbor-compliant formats.

Early Access Program members include leading commercial and academic testing labs including Emory Genetics Laboratory, GeneDx, LabCorp, Partners Healthcare and Quest Diagnostics. These collaborators provided important input into the development of the Ingenuity solution. A larger beta program will launch in early 2014, and interested laboratories can learn more at http://wptest.ingenuity.com/ngs-clinical-beta.

"I am excited to join my esteemed colleagues on the Scientific Advisory Board and to continue working closely with the Ingenuity team on the rollout of this powerful new application," said Dr. Sherri Bale, a medical geneticist who is Managing Dire
'/>"/>

SOURCE Qiagen N.V.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Financial Results, Appointments, Earnings Conferences, and Partnerships - Research Report on New Oriental Education & Technology, Acacia Research, DeVry, Capella Education, and Qiagen NV
2. Exosome Diagnostics and QIAGEN Partner to Launch Comprehensive Line of Biofluid Nucleic Acid Kits to Address Limitations of Tissue Biopsy in Clinical Research Market
3. QIAGEN Significantly Expands its Offering of Assay Panels for Next-generation Sequencing (NGS) Complemented by Ingenuity Analysis and Interpretation Capabilities
4. QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion Diagnostics
5. QIAGEN Enters Into Broad Collaboration Agreement With Lilly for the Development and Commercialization of Companion Diagnostics
6. QIAGEN Kicks Off Next-Generation Sequencing Initiative With Launch of a Series of Consumable Products to Improve NGS Workflows
7. QIAGEN Achieves Personalized Healthcare Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
8. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
9. QIAGEN and Cardinal Health Collaborate to Offer Molecular Diagnostic Products to Smaller and Mid-sized U.S. Hospitals
10. Pediatric Group Offers Consistent Vision Care Across Its Network with Spot Vision Screener
11. Dr. George O. Gavrila Opens Baltimore Tattoo Removal, Offers Astanza Duality Laser Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , November 25, 2014 ... Instruments Market by Power Source (Electric, Battery, Pneumatic), ... Cables, Blade, Burr, Cart), by Application (Orthopedic, ENT, ... published by MarketsandMarkets, the global Powered Surgical Instruments Market ... $1.6 Billion in 2014 and is expected to ...
(Date:11/26/2014)... , Nov. 25, 2014 Nanomix ... on the development of mobile diagnostic tests ... in hospital and pre-hospital settings, today announced ... 13485:2003 certification.  The certification was awarded by ... the world,s leading certification bodies. ...
(Date:11/26/2014)... OAKS, Calif. and LONDON , ... ) and AstraZeneca (NYSE: AZN ) today announced ... evaluating two doses of brodalumab in more than 1,800 patients ... with both Stelara ® (ustekinumab) and placebo at week ... brodalumab weight-based analysis group were each shown to be superior ...
Breaking Medicine Technology:Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Nanomix Receives ISO 13485:2003 Certification 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
(Date:11/27/2014)... PITTSBURGH, PA (PRWEB) November 27, 2014 ... suffer the embarrassing side effects of urinary incontinence," said ... to it and developed this specialized accessory to prevent ... developed the Incontinence to absorb urine leakage. This prevents ... wearer from potential embarrassment. The pad ensures that the ...
(Date:11/27/2014)... Randy Dotinga HealthDay Reporter , ... seem pre-wired to acquire a second language, new research suggests. ... will likely gain a brain boost, the small study finds. ... learning," said study co-author Ping Li, co-director of the Center ... it,s even more interesting, Li said, that "the brain networks ...
(Date:11/27/2014)... Dennis Thompson HealthDay Reporter ... vaccine appears to be safe and produces an immune system ... to early clinical trial results reported by the U.S. National ... clinical trial for the vaccine paves the way for field-testing ... Sierra Leone as early as January, said Dr. Anthony Fauci, ...
(Date:11/27/2014)... In order to enable people to adapt to ... easy way to avoid touching a toilet seat and/or lid ... prototype of the patent-pending Toilet Tamer, a device that enables ... lid in a more sanitary manner. It avoids direct contact ... it promotes good hygiene and peace of mind. The portable ...
(Date:11/27/2014)... 2014 Jeffrey Carlini has practiced ... Charlotte area providing audits, reviews, compilations, tax preparation, ... of varying size across numerous industries. Jeff has ... all of their accounting and tax needs. , ... ProAdvisor Program. When asking Mr. Carlini about his ...
Breaking Medicine News(10 mins):Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3Health News:Jeffrey Carlini becomes Intuit Proadvisor and receives QuickBooks certification 2
... the length of time spent using mobile telephones has ... (RF) radiations.// It has been proposed that a precautionary ... at present, there is no convincing scientific data to ... ,In view of the proximity between radio-frequency source ...
... and resultant facial scarring. A new study in the ... the American Society for Dermatologic Surgery//, reports that patients ... showed significant improvement of mild to severe acne scars ... as facial resurfacing, dermabrasion and chemical peels. ...
... elbow has been enjoying the spot light following ace cricketer ... However, the condition is not uncommon in the sports arena//. ... called in medical parlance, is an affliction where the outer ... a result of a specific strain, overuse or a direct ...
... blood pressure (BP) increase is one of the most ... most patients the condition, although urgent, is not an ... no guidelines on how to treat patients with acute ... cause of excessive hypertension and therefore antianxiety treatment may ...
... Researchers from Children’s Hospital of Boston have reconstructed ... The researchers used amniotic fluid for growing the ... these living tissues into lambs, while they were ... is used for altering birth defects. Undifferentiated stem ...
... yeast strains might have spawned an outbreak of disease ... British Columbia, Howard Hughes Medical Institute geneticists at Duke ... is normally restricted to the tropics and subtropics. ... in the pathogen's expansion may provide a useful model ...
Cached Medicine News:Health News:Mobile phones may influence normal brain functioning 2Health News:Tennis elbow not new among cricketers, say experts 2Health News:Anti-anxiety treatment found effective in lowering blood pressure 2Health News:Sex Played A Vital Role For Evolution Of Infectious Diseases 2
... HypercleanTM 22 fume containment system ... a one- or two-person work ... containment system comes complete ... four charcoal filters. (For replacement ...
Surgical-grade stainless steel disposable concentric needle with Trocar tip has an insulated platinum-alloy core and two attached 61-cm (24-in) lead wires. Needles sold in packages of 20....
... Rotavirus is the most common ... for 5% of pediatric visits ... children under 5 years. ImmunoSTAT! ... to rule in or rule ...
... test delivers 100% specificity and 100% ... minutes. With as many as ... follow-up, this assay provides a test ... to detection and treatment while reducing ...
Medicine Products: